CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
REVENUES:
Subscription and advertisement revenues	$ 1,357	$ 1,173	$ 2,218
Royalties from product sales	719	398	367
Grant income	4,502	3,297	1,573
Sale of research products and services	458	376	276
Total revenues	7,036	5,244	4,434
Cost of sales	(1,107)	(837)	(793)
Gross Profit	5,929	4,407	3,641
OPERATING EXPENSES:
Research and development	(42,604)	(37,533)	(26,609)
Acquired in-process research and development	0	0	(17,459)
General and administrative	(29,134)	(17,556)	(15,559)
Total operating expenses	(71,738)	(55,089)	(59,627)
Loss from operations	(65,809)	(50,682)	(55,986)
OTHER INCOME/(EXPENSES):
Interest income/(expense), net	(640)	(89)	0
BioTime's share of losses in equity method investment in Ascendance	(35)	0	0
Gain on investment (Note 12)	3,694	0	0
Other income/(expense), net	(160)	(384)	(204)
Total other income/(expense), net	3,159	(473)	(204)
LOSS BEFORE INCOME TAX BENEFIT	(62,650)	(51,154)	(56,191)
Deferred income tax benefit	4,516	7,376	3,281
NET LOSS	(58,134)	(43,779)	(52,910)
Net loss attributable to non-controlling interest	11,143	7,367	9,026
NET LOSS ATTRIBUTABLE TO BIOTIME, INC.	(46,991)	(36,412)	(43,883)
Dividends on preferred stock	(415)	(87)	0
NET LOSS ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ (47,406)	$ (36,499)	$ (43,883)
BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share)	$ (0.59)	$ (0.55)	$ (0.81)
WEIGHTED AVERAGE NUMBER OF COMMON STOCK OUTSTANDING: BASIC AND DILUTED (in shares)	79,711	66,467	54,226